NCT00537082 - Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS) | Biotech Hunter

Enrollment

171

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

February 28, 2010

Conditions

Multiple Sclerosis

Interventions

DRUG

FTY720

Administered orally once daily for 6 months

DRUG

Placebo

Administered orally once daily for 6 months

Trial Locations (18)

Unknown

Novartis Investigative site, Sapporo

276-8524

Novartis Investigative Site, Chiba

791-0295

Novartis Investigative Site, Ehime

807-8555

Novartis Investigative Site, Fukuoka

371-8511

Novartis Investigative Site, Gunma

650-0017

Novartis Investigative Site, Hyōgo

305-8576

Novartis Investigative Site, Ibaraki

259-1193

Novartis Investigative Site, Kanagawa

604-8453

Novartis Investigative Site, Kyoto

616-8255

Novartis Investigative Site, Kyoto

951-8520

Novartis Investigative Site, Niigata

020-8505

Novartis, Numakunai

556-0016

Novartis Investigative Site, Osaka

589-8511

Novartis Investigative Site, Osaka

329-0498

Novartis Investigative Site, Tochigi

145-0065

Novartis Investigative Site, Tokyo

162-8666

Novartis Investigative Site, Tokyo

641-8510

Novartis Investigative Site, Wakayama